UA29446C2 - Засіб для інгібування тромбіну - Google Patents

Засіб для інгібування тромбіну

Info

Publication number
UA29446C2
UA29446C2 UA94129200A UA94129200A UA29446C2 UA 29446 C2 UA29446 C2 UA 29446C2 UA 94129200 A UA94129200 A UA 94129200A UA 94129200 A UA94129200 A UA 94129200A UA 29446 C2 UA29446 C2 UA 29446C2
Authority
UA
Ukraine
Prior art keywords
drug
thrombin inhibition
thrombin
inhibition
discovery
Prior art date
Application number
UA94129200A
Other languages
English (en)
Russian (ru)
Inventor
Даніел Джон СОЛЛ
Даниел Джон Солл
Джеральд Флойд СМІТ
Джеральд Флойд Смит
Original Assignee
Елі Ліллі Енд Компані
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елі Ліллі Енд Компані, Эли Лилли Энд Компани filed Critical Елі Ліллі Енд Компані
Publication of UA29446C2 publication Critical patent/UA29446C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Винахід стосується методів інгібування тромбіну. Він базується на відкритті сполук, що є інгібіторами тромбіну та мають біологічну активність при оральному застосувані.
UA94129200A 1993-12-21 1994-12-19 Засіб для інгібування тромбіну UA29446C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,394 US5441965A (en) 1993-12-21 1993-12-21 Methods of inhibiting thrombin

Publications (1)

Publication Number Publication Date
UA29446C2 true UA29446C2 (uk) 2000-11-15

Family

ID=22623580

Family Applications (1)

Application Number Title Priority Date Filing Date
UA94129200A UA29446C2 (uk) 1993-12-21 1994-12-19 Засіб для інгібування тромбіну

Country Status (21)

Country Link
US (3) US5441965A (uk)
EP (1) EP0664126B1 (uk)
JP (1) JPH07223947A (uk)
KR (1) KR950016744A (uk)
CN (1) CN1078070C (uk)
AT (1) ATE150308T1 (uk)
AU (1) AU693822B2 (uk)
CA (1) CA2138493A1 (uk)
CZ (1) CZ287725B6 (uk)
DE (1) DE69402173T2 (uk)
DK (1) DK0664126T3 (uk)
ES (1) ES2102154T3 (uk)
GR (1) GR3023537T3 (uk)
HU (1) HU224915B1 (uk)
IL (1) IL112048A (uk)
NO (1) NO313081B1 (uk)
NZ (1) NZ270185A (uk)
RU (1) RU94045846A (uk)
TW (1) TW321601B (uk)
UA (1) UA29446C2 (uk)
ZA (1) ZA9410084B (uk)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
DE69435137D1 (de) 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5545641A (en) * 1994-10-20 1996-08-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of bradykinin
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
DE69622472T2 (de) * 1995-06-07 2003-02-06 Lilly Co Eli Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor
US5840747A (en) * 1995-06-07 1998-11-24 Eli Lilly And Company Calcium channel antagonists
US6545027B1 (en) * 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
WO1997025033A1 (en) 1995-10-31 1997-07-17 Eli Lilly And Company Antithrombotic diamines
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
JP2001522373A (ja) 1997-04-30 2001-11-13 イーライ・リリー・アンド・カンパニー 抗血栓剤
ATE286395T1 (de) 1997-04-30 2005-01-15 Lilly Co Eli Antithrombotische mittel
AU7170898A (en) 1997-04-30 1998-11-24 Eli Lilly And Company Antithrombotic agents
AU7274098A (en) 1997-04-30 1998-11-24 Eli Lilly And Company Antithrombotic agents
US6103740A (en) * 1997-08-21 2000-08-15 Eli Lilly And Company Methods for lowering platelet counts
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CA2327670A1 (en) * 1998-04-08 1999-10-14 Darrel Lavern Allen Pulmonary and nasal delivery of raloxifene
FR2777784B1 (fr) * 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
CA2335295A1 (en) 1998-06-16 1999-12-23 Eli Lilly And Company Methods for increasing levels of acetylcholine
US6353003B1 (en) * 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
EP0997460B1 (en) * 1998-10-28 2002-12-11 Eli Lilly And Company Benzothiophene compounds as antithrombotic agents and intermediates
EP1175433B1 (en) 1999-05-04 2005-08-03 Strakan International Limited Androgen glycosides and androgenic activity thereof
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
TW321601B (uk) 1997-12-01
IL112048A (en) 1999-03-12
CZ322694A3 (en) 1995-09-13
HUT71344A (en) 1995-11-28
DK0664126T3 (da) 1997-09-01
CA2138493A1 (en) 1995-06-22
DE69402173T2 (de) 1997-07-17
CZ287725B6 (en) 2001-01-17
NO944932D0 (no) 1994-12-19
JPH07223947A (ja) 1995-08-22
CN1107704A (zh) 1995-09-06
ATE150308T1 (de) 1997-04-15
AU8155894A (en) 1995-06-29
GR3023537T3 (en) 1997-08-29
NO944932L (no) 1995-06-22
US5441965A (en) 1995-08-15
EP0664126B1 (en) 1997-03-19
HU224915B1 (en) 2006-04-28
US5508292A (en) 1996-04-16
DE69402173D1 (de) 1997-04-24
CN1078070C (zh) 2002-01-23
NZ270185A (en) 1997-07-27
EP0664126A1 (en) 1995-07-26
IL112048A0 (en) 1995-03-15
US5688813A (en) 1997-11-18
NO313081B1 (no) 2002-08-12
ES2102154T3 (es) 1997-07-16
HU9403675D0 (en) 1995-02-28
RU94045846A (ru) 1996-10-20
AU693822B2 (en) 1998-07-09
ZA9410084B (en) 1996-06-19
KR950016744A (ko) 1995-07-20

Similar Documents

Publication Publication Date Title
UA29446C2 (uk) Засіб для інгібування тромбіну
AP2000001889A0 (en) Substituted ozoazaheterocyclyl factor Xa inhibitors.
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
EP0820287A4 (en) THROMBIN INHIBITORS
PL332509A1 (en) Beta-sulphonyl-hydroxamic acids as inhibitors of intercellular substance metaloproteinases
HUT71105A (en) Mercaptoacylamino-substituted benzazepines condensed with heterocycles, process for preparing them and pharmaceutical compositions of enkephalinase and ace inhibitor activity containing said compounds
FI941580A0 (fi) Bisyklisiä ansamysiinejä
WO1994026723A3 (en) ras FARNESYL TRANSFERASE INHIBITORS
IL123002A0 (en) 1-Phenyl-2- phenylacetoxy- ethanone derivatives
LU91145I9 (uk)
IL148544A0 (en) Tyrosine derivatives
HU9203074D0 (en) 2-substituted indene-2-mercapto-acetamide being inhibitors of encefalinase and ace
GR3035774T3 (en) Substituted benzolactam compounds as substance p antagonists
EP0772590A4 (en) THROMBIN INHIBITORS
IL143545A0 (en) Thrombin inhibitors
AU1748792A (en) Phosphorus containing compounds as inhibitors of retroviruses
GR3031602T3 (en) Novel 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase.
AU5710696A (en) Platelet aggregation inhibitors
MX9801190A (es) Inhibidores de prolil endopeptidasa.
MXPA01006469A (es) Combinaciones de inhibidores de proteina de transferencia de ester colesterilico y derivados de acido fibrico para indicaciones cardiovasculares.